No Data
Sino Biopharm (01177.HK): The market application for the new indication of first-line treatment for advanced hepatocellular carcinoma with Anlotinib hydrochloride capsules combined with Apatinib injection has been accepted.
On November 21, Geneonline reported that Sino Biopharm (01177.HK) announced that the Phase III clinical study (ALTN-AK105-III-02) of the first class innovative drug anlotinib hydrochloride capsules developed independently by the group combined with pembrolizumab injection for first-line treatment of advanced hepatocellular carcinoma has completed the mid-term analysis as per protocol. The Independent Data Monitoring Committee (IDMC) has determined that both the primary endpoint progression-free survival (PFS) and overall survival (OS) have reached the protocol-specified efficacy threshold. Based on this positive outcome, the group has recently submitted it to the China National Medical Products Administration for drug review.
Express News | Sino Biopharmaceutical - Submitted a New Indication Application for Marketing to Cde for Anlotinib Hydrochloride Capsule
Sino Biopharm Injects 142 Million Yuan Into LaNova Medicines
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Express News | 中国生物制药：與禮新醫藥簽署股權投資及戰略合作協議
Sino biopharm (01177.HK) signed a private equity investment and global strategy cooperation agreement with Lixi Medicine.
On November 20, GELONGHUI reported that sino biopharm (01177.HK) announced that the group has signed a private equity investment and global strategy cooperation agreement with Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. ("Lixin Pharmaceutical"). Accordingly, the group will invest in Lixin Pharmaceutical using self-raised funds and has reached a strategic cooperation in mainland china for LM-108 and several potential innovative bispecific antibodies or antibody-drug conjugates (ADCs). Lixin Pharmaceutical announced on October 18, 2024, that it has completed C1 round financing of 0.3 billion yuan, with the raised funds intended to accelerate the development of clinical pipeline drugs and the construction of an innovation platform. According to the capital increase agreement...
No Data
No Data
